Dixarit

Quick links to important sections

Dixarit

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dixarit

Dixarit: Definition, Classification, and Composition

Property Description
Active ingredient Clonidine hydrochloride
Form Tablet (oral dosage form)
Pharmacological class α₂-Adrenergic Agonist
General purpose Cardiovascular and systemic tension regulation
Origin Synthetic drug, imidazoline derivative

Dixarit is a synthetic prescription medicine in the form of an oral tablet, primarily defined by its active ingredient, Clonidine hydrochloride. The medication is formally classified as an α₂-adrenergic agonist, which places it within the category of centrally acting sympatholytic agents.

Clonidine is an imidazoline derivative that is chemically synthesized. Dixarit is a single-ingredient product, containing only Clonidine hydrochloride as the therapeutic component. The drug’s classification as an α₂-agonist is clinically recognized for its ability to regulate systemic processes.


The Unique Purpose of a Centrally Acting Agent

The general benefit of Dixarit is to facilitate the control of conditions related to systemic tension by reducing central sympathetic outflow. This action is achieved because Clonidine acts primarily in the brainstem, making it a centrally acting agent that influences systemic vascular tone.

This mechanism distinguishes it from peripheral antihypertensives. By effectively "quieting" the central nervous system's command signals, Dixarit provides a foundational utility in stabilizing circulatory parameters. The therapeutic effect of Clonidine stems from its ability to decrease sympathetic nerve activity. This action results in a decrease in peripheral vascular resistance and a reduced heart rate, which is the desired outcome for conditions characterized by an overactive sympathetic response, establishing a more regulated vascular state.

What side effects are possible with Dixarit?

Dixarit (clonidine hydrochloride) is associated with a range of possible side effects, most of which are mild and tend to diminish with continued therapy.

Adverse Reactions

The most Very Common (ge 1/10) adverse reactions reported are dry mouth, sedation, and orthostatic hypotension. Common (ge 1/100 to < 1/10) effects include depression, dizziness, headache, constipation, nausea, vomiting, and erectile dysfunction. Less common effects include hallucinations, nightmares, pruritus, and Raynaud's phenomenon.

Serious Adverse Reactions

The most clinically significant safety risk is rebound hypertension following the abrupt cessation of therapy, particularly with higher doses. This can be severe and may be accompanied by symptoms like agitation, headache, and tremor. Caution is warranted in patients with pre-existing cardiovascular conditions, such as severe coronary insufficiency, recent myocardial infarction, or certain cardiac conduction disturbances (e.g., sinus bradycardia, AV block), which the drug may worsen. Severe bradyarrhythmia is a formal contraindication.

Safety Considerations

The sedative effects of Dixarit can affect the ability to drive or operate machinery, especially when combined with alcohol or other CNS depressants. Use in pregnancy and while breastfeeding is not generally recommended unless the potential benefit justifies the risks, as the drug passes into the placenta and breast milk. Due to a lack of sufficient data, the drug is not recommended for use in children and adolescents younger than 18 years.

Overdose and Emergency Response

Dixarit Overdose and when to Seek Help

The official regulatory profile for Dixarit (Clonidine) overdose defines a severe event primarily by its effects on the Central Nervous System (CNS) and the Cardiovascular System. Documented overdose presentations include profound somnolence, lethargy, and sedation, along with miosis (pinpoint pupils). Cardiovascular effects include severe bradycardia (slow heart rate) and hypotension (low blood pressure), which may follow a documented transient period of hypertension.


Classification Official Regulatory Documentation
Severity Classification Overdose can lead to life-threatening outcomes, including respiratory depression, apnoea, and cardiovascular collapse.
Population Notes Pediatric exposure is noted as a risk; even small amounts can cause significant toxicity.

Regulatory guidance mandates that a patient must seek immediate medical attention and contact emergency services for any suspected overdose. Urgent medical help is required because the official labeling states that no specific antidote is known. Management is strictly symptomatic and supportive, necessitating hospital monitoring of vital signs and cardiac function. Officially described supportive measures for recent ingestion may include gastric lavage or administration of activated charcoal to limit absorption.

Therapeutic Uses of Dixarit

What Dixarit Treats: Main Uses and Benefits

Dixarit (Clonidine) is applied to provide essential symptomatic relief across key therapeutic areas, primarily by addressing conditions characterized by periods of heightened symptoms or central nervous system tension.

The medication is commonly used to help with symptoms related to systemic imbalance and high systemic pressure, such as chronic hypertension. It is also applied in managing neuropsychiatric symptoms, including hyperactivity, restlessness, and motor or vocal tics, and is relevant for easing acute autonomic distress seen in contexts like substance detoxification. Furthermore, it offers supplementary support for certain types of severe, chronic pain and menopausal hot flashes.

“It is commonly used across conditions presenting with acute episodes and supports the patient during difficult episodes by easing distress.”

This application provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms. Dixarit may assist with maintaining stability and is generally used across domains where additional symptomatic support is needed.


Quick Fact: Relief for Autonomic and Behavioral Symptoms

Dixarit is considered relevant for easing symptom clusters that may become intense or disruptive, such as the acute physical manifestations of withdrawal and the behavioral excesses of hyperactivity.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Dixarit — Official Regulatory Information

Category Official Regulatory Statement
Populations for whom use is allowed Adults (18+ years) are the standard population for the licensed indications, such as menopausal flushing [Source: HPRA/Medsafe].
Populations for whom use is not recommended Pediatric population (under 18 years) is not recommended. Use in children and adolescents lacks sufficient evidence for its safety and efficacy for the standard Dixarit indications [Source: MHRA/HPRA].
Populations for whom use is contraindicated 1. Hypersensitivity: Patients with known hypersensitivity to clonidine hydrochloride or any excipients [Source: FDA/HPRA]. 2. Severe Bradyarrhythmia: Patients with severe bradyarrhythmia resulting from Sick Sinus Syndrome or Atrioventricular (AV) Block of the 2nd or 3rd degree [Source: Medsafe/HPRA].
Age-related eligibility rules Use in patients under 18 years is not recommended and is not established for the standard indications [Source: HPRA/MHRA].
Condition-specific eligibility rules Renal Impairment: Use is restricted to caution and often requires dosage adjustment in patients with chronic renal failure [Source: Health Canada/FDA].
Pregnancy and lactation eligibility status Pregnancy: Use is restricted; only administered if clearly needed and the benefit outweighs possible risks to the fetus [Source: FDA/MHRA]. Lactation: Use is not recommended as the drug is excreted in human milk [Source: HPRA/Medsafe].
Eligibility-related restrictions Use with caution in patients with severe coronary insufficiency, recent myocardial infarction, cerebral vascular disease, heart failure, depression, or disorders of cerebral/peripheral perfusion [Source: Health Canada/FDA].

Eligibility classifications (high-level)

Category Classification Details (As Defined in Official Documents)
Eligibility severity classification Contraindicated (Prohibited); Not Recommended (Pediatric/Lactation); Use with Caution (Renal/Cardiac Conditions); Conditional Use (Pregnancy).
Eligibility-context constraints Restricted based on: Cardiac Conduction Integrity, Renal Excretion Function, Age Group Classification, and Reproductive State.

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use Dixarit by establishing contraindications that prohibit use in patients with severe cardiac conduction issues or drug hypersensitivity. Beyond these prohibitions, eligibility is limited by restrictions on age (not recommended for children) and is conditional upon the presence of pre-existing organ dysfunction or specific cardiovascular and psychiatric comorbidities, requiring regulatory-mandated caution. These official statements categorize the adult population without these contraindicating or restrictive conditions as the primarily eligible user group.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dixarit (Clonidine) has documented interaction patterns that primarily involve pharmacodynamic effects on the central nervous system ( CNS) and cardiac function, as described in official regulatory labeling. Food does not influence the pharmacokinetics of Dixarit.

Documented Pharmacodynamic Interactions

Substance Category Officially Documented Interaction Outcome
CNS Depressants (e.g., Alcohol, Barbiturates) May potentiate the CNS depressive effects (additive sedation).
Cardiac Agents (e.g., Digitalis, Calcium Channel Blockers) Risk of additive bradycardia and AV block (conduction abnormalities).
Tricyclic Antidepressants ( TCAs) May reduce the hypotensive effect of Dixarit (antagonism).
Neuroleptics (Antipsychotic Agents) Orthostatic regulation disturbances may be induced or exacerbated.

Required Timing Constraint

Regulatory documents specify a sequential withdrawal requirement when co-administering Dixarit with Beta-blockers. The Beta-blocker should be withdrawn gradually several days before the gradual discontinuation of Dixarit to mitigate the risk of adverse effects upon cessation.

Population-Specific Consideration

For patients with severe impairment of renal function, the elimination half-life of Clonidine can be prolonged up to 41 hours, which is a documented change in the drug's pharmacokinetic profile due to impaired clearance.

Mechanism of Action

Dixarit (Clonidine) exerts its primary mechanism of action through the selective agonism of central alpha-2 adrenergic receptors (alpha2-AR). These receptors, located on the presynaptic membranes of neurons within the central nervous system, function as autoreceptors. Stimulation of the alpha2-AR activates inhibitory G-proteins, resulting in the suppression of adenylyl cyclase activity and a subsequent reduction in intracellular cyclic adenosine monophosphate (cAMP). This cascade ultimately leads to the inhibition of norepinephrine release into the synaptic cleft. The decreased noradrenergic transmission within the vasomotor center reduces central sympathetic outflow, causing systemic vasodilatory modulation. Additionally, Dixarit interacts with I1 imidazoline receptors in the medulla oblongata. This secondary interaction contributes to the modulation of heart rate variability and the attenuation of the physiological response to stress.

Dosage and Administration Information

Dixarit (clonidine hydrochloride) is administered exclusively via the oral route as an immediate-release tablet. The principles of its administration are defined by specific dosing schedules and a mandatory discontinuation protocol.


General Administration Protocol

The use of Dixarit typically begins with a low initial dose taken in divided doses throughout the day, often with the larger portion administered at bedtime. For the low-dose regimen, the starting total daily dose is commonly 50 micrograms (mu g), generally given as one 25 mu g tablet twice daily. Dosage adjustment, or titration, is a gradual process, with increments made at intervals of one week until the desired daily dose is reached. The maximum recommended daily dose for this regimen is 150 mu g. The tablets can be taken with or without food.


Required Procedural Constraints

A key procedural requirement is the slow withdrawal of the medicine. Procedural guidelines indicate that the drug must never be stopped abruptly to mitigate physiological rebound effects. Instead, the dose must be systematically tapered by gradual reduction over several days, such as a 3 to 7-day period.

Usage in certain patient groups requires modification of the standard regimen. For older adults and individuals with impaired kidney function, therapy should be initiated with a lower initial dose. This adjustment ensures that the initial usage is adapted to potential changes in drug clearance for a predictable administration pattern. Furthermore, specific formulations of clonidine, such as extended-release tablets, must always be swallowed whole and not crushed, chewed, or broken, as this alters the intended drug delivery profile.

Recent Clinical Evidence

Research evidence / Overview of studies for Dixarit


Menopausal Flushing (Hot Flashes)

Research exploring how symptoms change over time was applied in studies examining patient-reported experiences. Dixarit was studied for how the agent was observed in conditions characterized by fluctuating or episodic manifestations, specifically focusing on outcomes related to physical discomfort like hot flashes. The research examined patterns observed in women experiencing these outcomes capturing phases of heightened symptom activity. Studies were conducted during periods of increased symptom activity to monitor how the frequency and intensity of symptoms may evolve in the observed populations.

The evidence suggests that in some studies, Dixarit was associated with patterns of change that were monitored during the study period related to patient-reported outcomes describing perceived discomfort (like hot flashes). The data show patterns related to changes in outcomes reflecting daily functioning or activity level as reported by participants in the research.

However, the evidence is limited when considering the full scope of this condition. Follow-up durations were limited in many of the trials, meaning long-term effects are not fully established. Evidence quality varies across studies, and certainty remains low regarding some aspects of its use. Results apply only to the populations studied, and comparative evidence is lacking. Findings describe group patterns, not personal outcomes.


Migraine Prevention

Dixarit was evaluated in studies that have applied in studies examining patient-reported experiences of severe headaches. Research examined how the medication was observed in people with conditions involving periods of heightened symptoms, specifically looking at outcomes describing episodic or acute changes in their headache patterns. These studies explored outcomes describing episodic or acute changes.

The evidence suggests that Dixarit was observed in some studies for outcomes describing episodic or acute changes over defined time intervals. These findings describe patterns observed in the studies that were related to outcomes linked to inflammatory or irritative states. The data show patterns related to a change in headache frequency measured during the study period, which contributes to the broader evidence landscape for this condition.

Despite these findings, the sample sizes were modest in some of the research, and findings were mixed across various studies on this topic. The data are still emerging for this use, and certainty remains low regarding its overall pattern of effect. Research does not determine whether an individual will respond similarly to the group findings; rather, the evidence highlights what is known — and what is still uncertain.

Key Studies & References

  1. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis
  2. Technical Review - Drug Treatments for the Prevention of Migraine Headache - NCBI - NIH
  3. Review of Guidelines on Clonidine for Various Indications (Summarizing NAMS, NICE, etc.)
  4. Dixarit Product Monograph (Data Sheet - Clonidine hydrochloride) [Regulatory Document]

Frequently Asked Questions (FAQ)

Common questions about Dixarit (FAQ)


Q: What is the main medical purpose of Dixarit, according to regulatory documents?

A: According to official regulatory documents, the primary medical purpose of Dixarit is for the prophylactic management of migraine or recurrent vascular headache. It is also indicated for the management of vasomotor symptoms, such as flushing, which are often associated with menopause.


Q: Why do people sometimes mention Dixarit in discussions about nerve discomfort?

A: The active ingredient in Dixarit works by stimulating alpha-2 adrenergic receptors in the central nervous system (CNS), which reduces sympathetic outflow. Because this mechanism affects various nerve signaling pathways, it has been explored in discussions related to a range of physiological responses.


Q: What is the chemical classification of the active ingredient in Dixarit?

A: The active ingredient in Dixarit, clonidine, is chemically classified as an imidazole derivative. Functionally, official documents describe it as a central alpha-2 adrenergic receptor agonist, which means it works by activating specific receptors in the brain.


Q: What are the most common non-serious side effects reported by regulatory agencies for Dixarit?

A: Official product information lists several common adverse events reported in clinical studies. These include somnolence (sleepiness), dry mouth, fatigue, headache, constipation, and dizziness. These are generally considered the most frequently reported non-serious effects.


Q: Can Dixarit cause unusual changes in appetite?

A: Yes, official regulatory documents list a decreased appetite as a reported adverse reaction observed in clinical studies involving the use of Dixarit.


Q: Does Dixarit interact with common pain medications like ibuprofen?

A: Official information indicates that non-steroidal anti-inflammatory drugs (NSAIDs), which include common pain relievers like ibuprofen, may decrease the blood pressure-lowering effect of clonidine.


Q: Are there any known interactions between Dixarit and herbal supplements?

A: Regulatory documents contain cautions regarding the co-administration of certain herbal supplements like St. John's Wort or Yohimbe due to the potential for adverse interactions. These interactions could lead to effects such as an unintended lowering of blood pressure.


Q: How long after starting Dixarit should a patient typically expect to notice its effects?

A: Official labeling for clonidine indicates that when used for its effect on blood pressure, the effect is typically observed relatively quickly, within 30 to 60 minutes after taking an oral dose. The time required to feel the full therapeutic effect for other specific conditions may vary.


Q: Is Dixarit intended for continuous long-term use, based on official information?

A: While some official drug labels indicate that there are no known problems associated with long-term use, the duration of clinical trials for conditions like menopausal flushing or migraine has often been limited. This means that the long-term effects for these specific indications are not fully established in research.


Q: What are the contraindications listed for Dixarit in regulatory documents?

A: Regulatory documents state that Dixarit is contraindicated (should not be used) in patients who have a known hypersensitivity or allergic reaction to clonidine hydrochloride or any other component found in the formulation of the tablets.


Q: What are the official safety classifications for Dixarit regarding use during pregnancy?

A: Official regulatory agencies provide classification systems for use during pregnancy. The oral tablet formulation of clonidine has been assigned to Pregnancy Category C by the U.S. FDA and Category B3 by the Australian TGA.


Q: Is there information available on Dixarit being transferred through breast milk?

A: Yes, official information confirms that clonidine is excreted into human milk. Regulatory data suggests that the concentration of the drug found in breast milk is approximately twice the concentration found in the mother's plasma.


Q: What are the recommended storage conditions for Dixarit medicine (temperature, humidity)?

A: Official product information states that Dixarit tablets should be stored at controlled room temperature. This is generally defined as a temperature between 15 C to 30 C (59 F to 86 F).


Q: Is it normal to experience dry mouth or excessive sleepiness after starting Dixarit?

A: Yes, dry mouth and somnolence (sleepiness) are specifically listed in official regulatory documents as two of the most common adverse reactions reported in clinical studies involving Dixarit.


Q: Why do some online resources categorize Dixarit as a psychotropic drug?

A: The mechanism of action involves affecting the activity of the neurotransmitter norepinephrine in the brain. Because this neurotransmitter influences central nervous system functions, including arousal and emotional states, some resources may refer to it as a psychotropic agent.


Q: Is Dixarit associated with any potential changes in mood or emotional state?

A: Yes, official documentation reports that adverse reactions observed in clinical trials included potential changes in mood or emotional state. These reactions include emotional disorder, irritability, and depression.


Q: Are there any known sensitivities or allergic reactions to the non-active ingredients in Dixarit?

A: Official regulatory documents state that Dixarit is contraindicated if a person has a known hypersensitivity or allergic reaction not only to clonidine hydrochloride but also to any component of the formulation, which includes the non-active ingredients.


Q: Is there a risk of dependence or withdrawal symptoms with Dixarit?

A: Official information indicates that abrupt discontinuation of Dixarit can cause a withdrawal syndrome (or physiological rebound effects). Regulatory information requires that the discontinuation of the medication involves a systematic tapering schedule.


Q: What is the information regarding Dixarit and the potential for long-term heart rate effects?

A: A slowing of the pulse rate is a commonly observed effect during therapy. However, official information related to long-term treatment generally suggests that effects on cardiac output tend to return toward baseline values over time.


Q: Does Dixarit interact with high blood pressure medications?

A: Yes, official labeling states that Dixarit may interact with other antihypertensive agents (medicines used to lower blood pressure), such as beta-blockers and calcium channel blockers. These interactions can increase the risk of side effects like bradycardia (slow heart rate) and heart conduction abnormalities.


Q: If someone stops taking Dixarit, how long does the drug remain active in the body?

A: The rate at which the body eliminates the active ingredient, clonidine, is measured by its terminal elimination half-life. For the general population, this half-life is reported to range from 5 to 25.5 hours.


Q: Is Dixarit suitable for the elderly population, according to drug labels?

A: Medical guidelines, such as the Beers Criteria, identify clonidine as a potentially inappropriate medication for older adults (65 years and older) when used for high blood pressure. This is due to a high risk of CNS adverse effects (effects on the brain and nervous system), slow heart rate (bradycardia), and sudden drop in blood pressure when standing (orthostatic hypotension).


Q: What research themes have been explored regarding Dixarit in the last ten years?

A: Official product information indicates that Dixarit has been formally studied for the prophylactic management of migraine or recurrent vascular headache. It has also been explored in research for the management of vasomotor conditions like flushing associated with menopause.


Q: Is Dixarit generally considered to impair a person's ability to operate machinery?

A: Official safety information cautions patients about the potential for sedation, dizziness, or an accommodation disorder (an issue with eye focus). Regulatory information requires that patients exercise caution when operating heavy machinery or driving until they know how the medicine affects them.


Q: What official warning statements are included in the labeling for Dixarit?

A: Official regulatory labeling contains several warning statements. Key warnings include the risk of rebound hypertension (a rapid and dangerous rise in blood pressure) if the medication is stopped abruptly, the risk of hypotension (low blood pressure) and bradycardia (slow heart rate), and the need for caution in patients with pre-existing heart rhythm issues.


Q: Does the effectiveness of Dixarit depend on what time of day it is taken?

A: The official general administration protocol often recommends that the total daily dose be taken in divided amounts. Regulatory administration protocols note that the larger portion of the daily dose is often administered at bedtime.

How should Dixarit be stored and disposed of?

How to Store and Dispose of Dixarit

Dixarit (clonidine hydrochloride) tablets must be stored according to specific regulatory conditions to maintain their stability and effectiveness.

Storage Requirements

The medication requires storage at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The product must be protected from light and should be dispensed in a tight, light-resistant container. This medication must be stored safely out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Dixarit tablets should not be flushed down the toilet or poured down a sink. The preferred method for disposal is utilizing a local drug take-back program. If a take-back program is unavailable, the tablets should be mixed with an undesirable substance, such as coffee grounds or cat litter, sealed in a container, and then placed in household trash. All personal information must be removed from the prescription label prior to disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dixarit found in:

A-Z Index: